Oncology Trials

Phase III

Sponsor: Alliance for Clinical Trials in Oncology

Principal Investigator: Mylene Sy Go, M.D.

Description: Optimizing endocrine therapy for diverse Stage I-III hormone receptor-positive, HER2-negative patients with an additional support program comprised of text-message reminders and telephone-based counseling.

NCT04379570

Sponsor: Alliance for Clinical Trials in Oncology

Principal Investigator: Mylene Sy Go, M.D. 

Description: This trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit.

NCT05008848

Sponsor: Freenome Holdings, Inc.

Principal Investigator: Mylene Sy Go, M.D. 

Description: This is a diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.

NCT05254834

Description: A survey for oncology patients undergoing complementary and integrative medicine therapies.

Sponsor: National Heart, Lung and Blood Institute (NHLBI)

Principal Investigator: Omar Al Ustwani, M.D.

Description: Clinical data, blood and tissue samples will be collected from long-term participants to establish a biorepository to facilitate the study of the natural history of MDS.

NCT02775383

Phase III

Sponsor: ECOG-ACRIN Cancer Research Group

Principal Investigator: Mylene Sy Go, M.D.

Description: This trial studies how well paclitaxel, trastuzumab and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery after pre-operative chemotherapy and HER2-targeted therapy.

NCT04266249

Phase III

Sponsor: Veru, Inc.

Principal Investigator: Mylene Sy Go, M.D.

Description: To demonstrate the efficacy of enobosarm in the treatment of androgen receptor-positive (AR+) and estrogen receptor-positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression-free survival (rPFS).

NCT04869943

Sponsor: iSpecimen

Principal Investigator: Mylene Sy Go, M.D. 

Description: This trial uses a two-tube blood draw from mTNBC patients who are treatment-naive or early in treatment for novel research purposes.

NCT03848962

Phase III

Sponsor: Alliance for Clinical Trials in Oncology

Principal Investigator: Shailja Roy, M.D.

Description: This trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (MMR).

NCT02912559

Phase II/III

Sponsor: NRG Oncology

Principal Investigator: Mylene Sy Go, M.D.

Description: This trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery.

NCT04068103

Phase II

Sponsor: SWOG Cancer Research Network

Principal Investigator: Mylene Sy Go, M.D.

Description: This trial studies whether atezolizumab in combination with talazoparib works better than atezolizumab alone as maintenance therapy for patients with SLFN11-positive extensive-stage small cell lung cancer.

NCT04334941

Phase III

Sponsor: ECOG-ACRIN Cancer Research Group

Principal Investigator: Omar Al Ustwani, M.D.

Description: This trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK).

NCT02201992

Sponsor: Alliance for Clinical Trials in Oncology

Principal Investigator: Omar Al Ustwani, M.D.

Description: The ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery.

NCT02194738

Phase III

Sponsor: Veru, Inc.

Principal Investigator: Mylene Sy Go, M.D.

Description: To demonstrate the efficacy of VERU-111 (sabizabulin) in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have failed prior treatment with at least one androgen receptor targeting agent as measured by radiographic progression-free survival.

NCT04844749